A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.
NCT ID: NCT00531934
Last Updated: 2015-02-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
147 participants
INTERVENTIONAL
2007-10-31
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash
NCT00803842
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT00153803
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
NCT01328951
A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
NCT01998919
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
NCT01465802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Doxycline
100mg po daily
erlotinib [Tarceva]
150mg po daily
2
erlotinib [Tarceva]
150mg po daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycline
100mg po daily
erlotinib [Tarceva]
150mg po daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* confirmed non-small cell lung cancer;
* failure after first line chemotherapy for advanced disease, and scheduled for second line therapy with Tarceva.
Exclusion Criteria
* history of significant heart disease;
* any other malignancies (other than adequately treated squamous cell skin cancer, or in situ cancer of the cervix);
* history of allergic reactions to tetracyclines.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Antibes, , France
Bordeaux, , France
Bordeaux, , France
Brest, , France
Caen, , France
Chalon-sur-Saône, , France
Chartres, , France
Draguignan, , France
Gap, , France
Gleizé, , France
Limoges, , France
Metz, , France
Nîmes, , France
Paris, , France
Paris, , France
Paris, , France
Perpignan, , France
Périgueux, , France
Pierre-Bénite, , France
Pontoise, , France
Rennes, , France
Rouen, , France
Tours, , France
Vannes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML20829
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.